FDA Approves Keytruda (pembrolizumab) Plus Lenvima (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
KENILWORTH& WOODCLIFF, N.J.--(BUSINESS WIRE) July 22, 2021 -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the combination of... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 22, 2021 Category: Drugs & Pharmacology Source Type: news
Screening Often Misses Endometrial Cancer in Black Women
TUESDAY, July 20, 2021 -- A noninvasive method of screening for endometrial cancer often fails to detect signs of it in Black women, a new study says.
The findings raise questions about the use of transvaginal ultrasound (TVUS) to determine the need... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - July 20, 2021 Category: General Medicine Source Type: news
Ultrasound misses endometrial cancer in Black women
Using transvaginal ultrasound to measure endometrial thickness to determin...Read more on AuntMinnie.comRelated Reading:
Radiologists can help reduce disparities around COVID-19
6 ways to address healthcare inequality in radiology
Hysterosalpingo contrast ultrasound shows promise in infertility exams
Ultrasound steps up in COVID-19 pandemic
Model predicts metastases in endometrial cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - July 15, 2021 Category: Radiology Source Type: news
Screening often misses endometrial cancer in Black women
In this study using a simulated cohort, TVUS endometrial thickness screening missed over four times more cases of endometrial cancer among Black women versus White women owing to the greater prevalence of fibroids and non-endometrioid histology type that occurs among Black women. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 15, 2021 Category: Cancer & Oncology Source Type: news
Racial Disparities Persist in Endometrial Cancer Care Racial Disparities Persist in Endometrial Cancer Care
Women who were Black, Latina, American Indian, or Alaska Native were less likely than White women to receive guidelines-adherent treatment for endometrial cancer, a study shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 1, 2021 Category: Cancer & Oncology Tags: Ob/Gyn & Women ' s Health News Source Type: news
Lenvatinib + pembrolizumab is not cost effective for recurrent MSS endometrial cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 1, 2021 Category: Drugs & Pharmacology Source Type: news
Lower BMI Cutoff Tied to Endometrial Cancer in Chinese Women
Lower obesity threshold of BMI ≥25 kg/m2 tied to increased risk of endometrial cancer in Asian women presenting with postmenopausal bleeding (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - June 30, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Journal, Source Type: news
Lower BMI Cutoff Tied to Endometrial Cancer in Chinese Women
WEDNESDAY, June 30, 2021 -- Body mass index (BMI) ≥25 kg/m2 is independently associated with increased risk of endometrial cancer among Chinese women presenting with postmenopausal bleeding, according to a study published online June 30 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 30, 2021 Category: Pharmaceuticals Source Type: news
Postmenopausal bleeding may be a sign of endometrial cancer in obese Asian women
(The North American Menopause Society (NAMS)) The link between obesity and the risk of endometrial cancer has been well documented. A new study, however, shows that an even lower body mass index (BMI) than previously thought can signal an increased risk in Asian women with postmenopausal bleeding. Study results are published online today in Menopause, the journal of The North American Menopause Society (NAMS). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 30, 2021 Category: International Medicine & Public Health Source Type: news
Consumer Health: Treating polycystic ovary syndrome
Polycystic ovary syndrome is a hormonal disorder common among women of reproductive age. Complications can include infertility, gestational diabetes or pregnancy-induced high blood pressure, miscarriage or premature birth, and endometrial cancer. Signs and symptoms of polycystic ovary syndrome vary. A diagnosis is made when women experience at least two of these signs: Irregular periods.Elevated levels of male [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 11, 2021 Category: Databases & Libraries Source Type: news
Pembrolizumab in dMMR/MSI-H unresectable or metastatic endometrial cancer: substantial gain in life-years at acceptable cost in the US
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 30, 2021 Category: Drugs & Pharmacology Source Type: news
Monthly News Roundup - April 2021
GSK’s Checkpoint Inhibitor Jemperli Gains Approval for Endometrial Cancer
The FDA has given accelerated approval to GSK’s Jemperli (dostarlimab-gxly), a programmed death receptor-1 (PD-1) blocking antibody used to treat adults with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 30, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Immunotherapy for dMMR Endometrial Cancer
Jemperli approved for dMMR endometrial cancer that progressed after platinum - containing chemotherapy treatment (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 24, 2021 Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, FDA Approvals, Source Type: news
FDA Approves Immunotherapy for dMMR Endometrial Cancer
FRIDAY, April 23, 2021 -- The anti-programmed death receptor 1 (PD-1) monotherapy Jemperli (dostarlimab) received approval for treatment of mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer that has progressed after treatment... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 23, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves New Immunotherapy for Endometrial Cancer FDA Approves New Immunotherapy for Endometrial Cancer
The accelerated approval for dostarlimab is for use in patients with recurrent or advanced endometrial cancers with deficient mismatch repair (dMMR).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 23, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
